Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
Academic Editor: Frank Dor
Although cadaveric lung transplantation (CLT) offers acceptable prospects for 5-year survival, chronic rejection and donor shortages remain major problems. In an effort to address the donor shortage issue, living-donor lobar lung transplantations (LDLLT) have been performed in some institutions. As of 2006, LDLLT has been performed in approximately 300 patients worldwide. The survival appears to be similar to or better than International Society for Heart and Lung Transplantation registry data on CLT. Because of the possible serious complications after donor lobectomy, LDLLT should be performed only for very sick patients by a well-prepared program. This type of procedure can be applied to restrictive, obstructive, infectious, and hypertensive lung diseases for both pediatric and adult patients who would die soon otherwise.